Novartis dumps AveXis program for Rett syndrome after failing repeat round of preclinical testing
Say goodbye to AVXS-201.
The Rett syndrome gene therapy drug made by AveXis — the biotech that was bought, kept separate, then renamed and finally …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
